Steven Cohen Akebia Therapeutics, Inc. Put Options Transaction History

Point72 Asset Management, L.P.

2 transactions

Quarter	Operation	Price Per put	puts change	puts Held	SEC Form
Q2 2022 Aug 15, 2022	SELL	$0.32 - $0.67 $152,160 - $318,585	-475,500 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$0.72 - $2.93 $342,360 - $1.39 Million	475,500 New	475,500 $341,000

127

56.7M

937K

743K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $173M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.